Retrospective analysis of direct-acting oral anticoagulants (DOACs) initiation timing and outcomes after thrombolysis in high-and intermediate-risk pulmonary …
A Wolfe, A Phillips, DM Tierney… - Clinical and Applied …, 2023 - journals.sagepub.com
Direct-acting oral anticoagulants (DOACs) are prescribed in the treatment of venous
thromboembolism, including pulmonary embolism (PE). Evidence is limited regarding the …
thromboembolism, including pulmonary embolism (PE). Evidence is limited regarding the …
Reducing length of stay with the direct oral anti-coagulants in low and intermediate risk pulmonary embolism: a single center experience
J Filopei, EE Bondarsky, M Ehrlich, M Islam… - Journal of Thrombosis …, 2020 - Springer
Direct oral anti-coagulants (DOACs) reduce hospital length-of-stay (LOS) in patients with
acute pulmonary embolism (PE) in clinical trials. There is a paucity of literature describing …
acute pulmonary embolism (PE) in clinical trials. There is a paucity of literature describing …
Prescription patterns of direct oral anticoagulants in pulmonary embolism: A prospective multicenter French registry
R Chopard, JN Andarelli, S Humbert, N Falvo… - Thrombosis …, 2019 - Elsevier
Background Data regarding the use of direct oral anticoagulants (DOACs) for the treatment
of acute pulmonary embolism (PE) are sparse. We conducted a prospective multicentre …
of acute pulmonary embolism (PE) are sparse. We conducted a prospective multicentre …
Early prescription of direct oral anticoagulant for the treatment of intermediate-high risk pulmonary embolism: a multi-center, observational cohort study
R Chopard, M Badoz, C Eveno, F Ecarnot, N Falvo… - Thrombosis …, 2020 - Elsevier
Objectives The safety and efficacy of direct oral anticoagulants (DOACs) in intermediate-
high risk pulmonary embolism (PE) are unknown. The aims of the present study were to …
high risk pulmonary embolism (PE) are unknown. The aims of the present study were to …
Non-recommended dosing of direct oral anticoagulants in the treatment of acute pulmonary embolism is related to an increased rate of adverse events
R Chopard, G Serzian, S Humbert, N Falvo… - Journal of Thrombosis …, 2018 - Springer
Dose adjustment of direct oral anticoagulants (DOACs) is not required in the setting of acute
PE treatment according to the manufacturer's labelling, beyond the contraindication in …
PE treatment according to the manufacturer's labelling, beyond the contraindication in …
Outpatient treatment in low-risk pulmonary embolism patients receiving direct acting oral anticoagulants is associated with cost savings
R Ghazvinian, J Elf, S Löfvendahl… - Clinical and Applied …, 2020 - journals.sagepub.com
Direct oral anticoagulants (DOAC) are first line treatment for pulmonary embolism (PE).
Treatment of acute PE is traditionally hospital based and associated with high costs. The …
Treatment of acute PE is traditionally hospital based and associated with high costs. The …
The effect of off-label use of reduced-dose direct oral anticoagulants therapy in the treatment of pulmonary embolism comparable to standard-dose therapy
S Yamazoe, H Imai, Y Ogawa, N Kano, Y Murase… - Heart and Vessels, 2024 - Springer
Direct oral anticoagulants (DOACs) have been shown to be effective and safe in preventing
pulmonary embolism recurrence. In this single-center retrospective observational study, we …
pulmonary embolism recurrence. In this single-center retrospective observational study, we …
Direct oral anticoagulants for the treatment of pulmonary embolism in patients with renal impairment
B Rivera-Lebron, R Bauersachs - Thrombosis Research, 2021 - Elsevier
Pulmonary embolism (PE) is associated with adverse outcomes and substantial morbidity
and mortality. Patients with PE often have renal impairment because of shared risk factors …
and mortality. Patients with PE often have renal impairment because of shared risk factors …
Direct Oral Anticoagulants for Pulmonary Embolism
R Pizzi, LA Cimini, W Ageno, C Becattini - Hämostaseologie, 2024 - thieme-connect.com
Venous thromboembolism (VTE) is the third most common cardiovascular disease. For most
patients, the standard of treatment has long consisted on low-molecular-weight heparin …
patients, the standard of treatment has long consisted on low-molecular-weight heparin …
Contemporary anticoagulant treatment strategies in patients with acute pulmonary embolism at different risk for death
C Becattini, G Agnelli, M Diamanti, AP Maggioni… - Vascular …, 2023 - Elsevier
Introduction Availability of new treatment strategies for patients with acute pulmonary
embolism (PE) have changed clinical practice with potential influence in short-term patients' …
embolism (PE) have changed clinical practice with potential influence in short-term patients' …